{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:35:43Z","timestamp":1790181343016,"version":"4.1.0"},"reference-count":15,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Several case reports of COVID-19 in patients with myasthenia gravis (MG) have been documented. However, new-onset autoimmune MG following COVID-19 has been reported very rarely. We report one such case here. A 65-year-old man presented to us with dysphagia 6\u2009weeks following mild COVID-19. He was evaluated and diagnosed as antiacetylcholine receptor antibody (AchR) positive, non-thymomatous, generalised MG. He subsequently developed myasthenic crisis and improved after treatment with intravenous immunoglobulin, prednisolone and pyridostigmine. Systematic literature review showed eight more similar cases. Analysis of all cases including the one reported here showed these features: mean age 55.8 years, male gender (5), time interval between COVID-19 and MG (5\u201356\u2009days), generalised (5), bulbar and\/or ocular symptoms (4), anti-AchR antibodies (7) and antimuscle-specific kinase antibodies (2). All have improved with immunotherapy. Although, many hypothesis are proposed to explain causal relationship between the two, it could as well be sheer coincidence.<\/jats:p>","DOI":"10.1136\/bcr-2021-244146","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:59:34Z","timestamp":1626872374000},"page":"e244146","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-6252","authenticated-orcid":false,"given":"Y","family":"Muralidhar Reddy","sequence":"first","affiliation":[{"name":"Neurology, Care Hospital Banjara Hills, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh Kumar","family":"B","sequence":"additional","affiliation":[{"name":"Neurology, Care Hospital Banjara Hills, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Osman","sequence":"additional","affiliation":[{"name":"Neurology, Care Hospital Banjara Hills, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagarlapudi M K","family":"Murthy","sequence":"additional","affiliation":[{"name":"Neurology, Care Hospital Banjara Hills, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2025082703471595000_14.7.e244146.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30221-0"},{"key":"2025082703471595000_14.7.e244146.2","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front Neurol"},{"key":"2025082703471595000_14.7.e244146.3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mus.26918","article-title":"COVID-19 in patients with myasthenia gravis","volume":"62","author":"Anand","year":"2020","journal-title":"Muscle Nerve"},{"key":"2025082703471595000_14.7.e244146.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116888","article-title":"Myasthenic crisis in COVID-19","volume":"414","author":"Delly","year":"2020","journal-title":"J Neurol Sci"},{"key":"2025082703471595000_14.7.e244146.5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.7326\/L20-0845","article-title":"Myasthenia gravis associated with SARS-CoV-2 infection","volume":"173","author":"Restivo","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025082703471595000_14.7.e244146.6","doi-asserted-by":"crossref","unstructured":"Sriwastava S , Tandon M , Kataria S . New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol 2020:1\u20137.","DOI":"10.1007\/s00415-020-10263-1"},{"key":"2025082703471595000_14.7.e244146.7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.nrl.2020.04.003","article-title":"SARS-CoV-2 infection associated with diplopia and anti-acetylcholine receptor antibodies","volume":"35","author":"P\u00e9rez \u00c1lvarez","year":"2020","journal-title":"Neurologia"},{"key":"2025082703471595000_14.7.e244146.8","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.576153","article-title":"Postinfectious onset of myasthenia gravis in a COVID-19 patient","volume":"11","author":"Huber","year":"2020","journal-title":"Front Neurol"},{"key":"2025082703471595000_14.7.e244146.9","doi-asserted-by":"crossref","DOI":"10.1111\/ene.14721","article-title":"Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection","author":"Assini","year":"2021","journal-title":"Eur J Neurol"},{"key":"2025082703471595000_14.7.e244146.10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.7326\/L20-1298","article-title":"Musk antibody-associated myasthenia gravis with SARS-CoV-2 infection: a case report","volume":"174","author":"Muhammed","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025082703471595000_14.7.e244146.11","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.566308","article-title":"Is Guillain-Barr\u00e9 syndrome associated with COVID-19 infection? A systemic review of the evidence","volume":"11","author":"Abdullahi","year":"2020","journal-title":"Front Neurol"},{"key":"2025082703471595000_14.7.e244146.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"2025082703471595000_14.7.e244146.13","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"2025082703471595000_14.7.e244146.14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CND.0000000000000316","article-title":"Myasthenic syndrome caused by hydroxychloroquine used for COVID-19 prophylaxis","volume":"22","author":"Koc","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"key":"2025082703471595000_14.7.e244146.15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0028-3886.55567","article-title":"Thymectomy in myasthenia gravis","volume":"57","author":"Murthy","year":"2009","journal-title":"Neurol India"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-244146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:47:23Z","timestamp":1756291643000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-244146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,21]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/bcr-2021-244146"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-244146","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}